BioNTech Is Riding A Wave Of COVID-19 Vaccine Demand, But How Long Will It Last?

Company Will Earn Nearly $20bn In 2021

Booster shots could maintain Comirnaty sales in 2022, but a sharp decline is expected in follow years – and so BioNTech needs a long-term growth plan.

Stafford / United Kingdom - November 9 2020: Pfizer BioNTech Covid-19 vaccine concept. Syringe balanced on a fingertip and blurred company logos on the background. Selective focus.
Pfizer and BioNTech now expect to deliver 2.5 billion doses of Comirnaty this year, putting them far ahead of mRNA vaccine rivals Moderna. • Source: Alamy

BioNTech has raised its full-year revenue forecast from its record-breaking COVID-19 vaccine Comirnarty, and now expects to earn €16bn-€17bn ($19.7bn) in 2021.

That is a potential 7% uplift on its BioNTech’s previous forecast of €15.9bn, and in line with the increase its...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip